Sareum Holdings plc (SAR) ORD GBP0.0125

- Add to watchlist
- Create an alert
- This stock can be held in a




Business summary
Sareum Holdings plc is a United-Kingdom based holding company. It is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry, and medicinal chemistry. Its drug programs include Checkpoint Kinase 1 (Chk1), TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. The Checkpoint Kinase 1 (Chk1) inhibitor SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DNA damage response (DDR) network. The TYK2/JAK1 are both members of the Janus kinase (JAK) family of protein kinase enzymes with important roles in maintaining a healthy immune system. Both kinases promote inflammatory responses in autoimmune diseases, respiratory infections and tumor cell proliferation in certain cancers. Aurora+FLT3 Kinase Programme targets Acute Myeloid Leukemia (AML) and other blood cancers.
Contact details
Important dates
General stock information
- EPIC:
- SAR
- ISIN:
- GB00BMC3RJ87
- Market cap:
- £131.03 million
- Shares in issue:
- 68.07 million
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.